Page last updated: 2024-11-11

furaltadon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

furaltadon: structure; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

furaltadone : An oxazolidinone that is 1,3-oxazolidin-2-one substituted at position 1 by a (5-nitro-2-furyl)methylene]amino group and at position 5 by a morpholin-4-ylmethyl group. An antibacterial formerly used oraly but withdrawn due to toxicity, it is used topically (as the hydrochloride salt) for treatment of ear disorders. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9553856
CHEMBL ID1189513
CHEBI ID74803
SCHEMBL ID49268
MeSH IDM0051210

Synonyms (111)

Synonym
nsc53270
BRD-A67514145-003-03-3
nf-602
3795-88-8
2-oxazolidinone, (s)-,
levofuraltadone
2-oxazolidinone, (-)-,
nsc527986
nsc186663
furazoline
sepsinol
furazolin
furmetonol
nitrofuraltadone
nitrofurmeton
2-oxazolidinone, 5-(4-morpholinylmethyl)-3-[[(5-nitro-2-furanyl)methylene]amino]-
nitrofurmethone
furmethonol
f-150
nsc42388
altabactina
unifur
valsyn
2-oxazolidinone, 5-(morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-
ultrafur
furaltadone
altafur
medifuran
nitraldone
furmethanol
otifuril
ibifur
nsc-42388
furasol
5-(morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]oxazolidone
valsyn water mix
nf 260
darifur
139-91-3
5-(morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone
component of altapen
D02510
altafur (tn)
furaltadone (inn)
2-oxazolidinone, 5-(4-morpholinylmethyl)-3-[[(1e)-(5-nitro-2-furanyl)methylene]amino]-
5-(morpholinomethyl)-3-[(e)-(5-nitro-2-furyl)methyleneamino]oxazolidin-2-one
5-(morpholin-4-ylmethyl)-3-{[(1e)-(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one
5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)oxazolidone, (e)
5-(4-morpholinomethyl)-3-(5-nitro-2-furfurylideneamino)-2-oxazolidinone
brn 0363627
ai3-26829
furaltadon
5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)-2-oxazolidinone
5-(morpholinomethyl)-3-((5-nitro-furfurylidene)amino)-2-oxazolidinone
5-morpholinomethyl-3-(5-nitro-2-furfurylidine-amino)-2-oxazolidinone
nitrofurmethonum
nsc 42388
2-oxazolidinone, 5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)-
(+-)-5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)-2-oxazolidinone
einecs 205-384-5
2-oxazolidinone, 5-(4-morpholinylmethyl)-3-(((5-nitro-2-furanyl)methylene)amino)-
furaltadona [inn-spanish]
furaltadonum [inn-latin]
furaltadone [inn:ban]
valsyn (van)
5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)oxazolidone
ccris 1045
BSPBIO_000808
BPBIO1_000890
PRESTWICK3_000764
AB00514641
PRESTWICK2_000764
5-(morpholin-4-ylmethyl)-3-[(e)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
5-(4-morpholinylmethyl)-3-[(e)-(5-nitro-2-furanyl)methylideneamino]-2-oxazolidinone
A807595
HMS3264H17
5-morpholinomethyl-3-(5-nitrofurfurylideneamino)-2-oxazolidinone
nsc-759242
nsc759242
pharmakon1600-01505770
bdbm50392858
unii-5x4v82zn30
4-27-00-05556 (beilstein handbook reference)
furaltadona
furaltadonum
5x4v82zn30 ,
CHEBI:74803 ,
5-(morpholin-4-ylmethyl)-3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one
AKOS015903869
94107-51-4
furaltadone [inn]
furaltadone [who-dd]
furaltadone [mi]
(+/-)-5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)-2-oxazolidinone
CHEMBL1189513
CCG-214044
SCHEMBL49268
YVQVOQKFMFRVGR-VGOFMYFVSA-N
component of altapen (salt/mix)
(.+/-.)-5-(morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone
5-(4-morpholinylmethyl)-3-([(5-nitro-2-furyl)methylidene]amino)-1,3-oxazolidin-2-one #
5-(morpholinomethyl)-3-(((5-nitrofuran-2-yl)methylene)amino)oxazolidin-2-one
AB00514641_03
AB00514641_02
SR-01000838850-3
furaltadone, vetranal(tm), analytical standard
J-007333
SBI-0207021.P001
CS-0013615
HY-B1148A
furaltadone (veterinary usage)

Research Excerpts

Overview

Furaltadone is an illicit veterinary drug. Shows toxic, carcinogenic, and mutagenic effects. metabolite 3-amino-5-morpholinomethyl-2-oxazolidone (AMOZ)(1)

ExcerptReferenceRelevance
"Furaltadone is an illicit veterinary drug that shows toxic, carcinogenic, and mutagenic effects, as does its metabolite 3-amino-5-morpholinomethyl-2-oxazolidone (AMOZ)(1). "( Cloning, expression, purification, and characterization of a novel single-chain variable fragment antibody against the 2-nitrobenzaldehyde derivative of a furaltadone metabolite in Escherichia coli.
Dong, J; Du, X; Lei, H; Li, Z; Liu, X; Shen, Y; Sun, Y; Wang, H; Xu, Z; Yang, W, 2012
)
2.02

Dosage Studied

The results showed that the adsorption efficiency of furaltadone reached 97% when the dosage of M-MWCNT was 0.

ExcerptRelevanceReference
"A single oral dosage of furaltadone and nitrofurazone (14."( Some pharmacokinetic data about furaltadone and nitrofurazone administered orally to preruminant calves.
Aerts, MM; Degen, M; Driessens, F; Nouws, JF; Vree, TB, 1987
)
0.86
" Less than 2% of the parent drug was present in the urine of animals dosed either intravenously or intramammarily."( In vivo and in vitro pharmacokinetics and fate of furaltadone in meat- and milk-producing animals.
Bevill, RF; Ng, LL; Perkins, EG, 1984
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mitogen-activated protein kinase 9Homo sapiens (human)IC50 (µMol)13.50000.00500.74755.2000AID692607
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
protein phosphorylationMitogen-activated protein kinase 9Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein ubiquitinationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 9Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 9Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 9Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 9Homo sapiens (human)
protein localization to tricellular tight junctionMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of podosome assemblyMitogen-activated protein kinase 9Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 9Homo sapiens (human)
inflammatory response to woundingMitogen-activated protein kinase 9Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleoplasmMitogen-activated protein kinase 9Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 9Homo sapiens (human)
cytosolMitogen-activated protein kinase 9Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 9Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 9Homo sapiens (human)
Schaffer collateral - CA1 synapseMitogen-activated protein kinase 9Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 9Homo sapiens (human)
nucleusMitogen-activated protein kinase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID692609Displacement of FITC-JIP peptide from human His-tagged JNK2alpha2 after 30 mins by fluorescence assay2012ACS medicinal chemistry letters, Aug-06, Volume: 3, Issue:9
From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules.
AID1323835Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID692616Inhibition of rat ERK2 using Ets1 (1 to 138) as substrate preincubated for 30 mins before [gamma-32P]-ATP addition measured after 10 mins by liquid scintillation counting2012ACS medicinal chemistry letters, Aug-06, Volume: 3, Issue:9
From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules.
AID692612Inhibition of p38MAPKalpha using GST-ATF2 (1 to 115) as substrate preincubated for 30 mins before [gamma-32P]-ATP addition measured after 10 mins by liquid scintillation counting2012ACS medicinal chemistry letters, Aug-06, Volume: 3, Issue:9
From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules.
AID1323834Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID692608Inhibition of human JNK2alpha2 using GST-c-jun (1 to 221) as substrate at saturating concentration preincubated for 30 mins before [gamma-32P]-ATP addition measured after 10 mins by liquid scintillation counting2012ACS medicinal chemistry letters, Aug-06, Volume: 3, Issue:9
From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules.
AID692607Inhibition of human JNK2alpha2 using GST-c-jun (1 to 221) as substrate preincubated for 30 mins before [gamma-32P]-ATP addition measured after 10 mins by liquid scintillation counting2012ACS medicinal chemistry letters, Aug-06, Volume: 3, Issue:9
From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (92)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (52.17)18.7374
1990's14 (15.22)18.2507
2000's10 (10.87)29.6817
2010's17 (18.48)24.3611
2020's3 (3.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.74 (24.57)
Research Supply Index4.63 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies5 (4.90%)4.05%
Observational0 (0.00%)0.25%
Other97 (95.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]